<?xml version="1.0"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:nw="http://www.newsweaver.ie">
<channel>
<title>Newsletter - Alzheimer Europe March 2026 newsletter</title>
<link>https://alzheimereurope.newsweaver.com/Newsletter/</link>
<atom:link href="https://alzheimereurope.newsweaver.com/Newsletter/rss/rss.xml" rel="self" type="application/rss+xml" />
<description></description>
<language>en-us</language>
<pubDate>31 Mar 2026 06:26:19 CEST</pubDate>
<lastBuildDate>31 Mar 2026 06:26:19 CEST</lastBuildDate>
<docs>https://alzheimereurope.newsweaver.com/Newsletter/rss.xml</docs>
<generator>Newsweaver</generator>
<managingEditor>info@alzheimer-europe.org ()</managingEditor>
<webMaster>support@newsweaver.ie (Newsweaver)</webMaster>
<ttl>60</ttl>
<nw:microsite>true</nw:microsite>
<item>
<title>Welcome</title>
<link>https://alzheimereurope.newsweaver.com/Newsletter/u2jivm37q9k?lang=en&amp;rss=true</link>
<description>Alzheimer Europe's March 2026 newsletter [ https://alzheimereurope.newsweaver.com/Newsletter/1d33r3wn7rd/external?lang=en ] [ https://alzheimereurope.newsweaver.com/Newsletter/1d33r3wn7rd/external?lang=en ] brings you the latest news on developments in the dementia field, across Europe and beyond.

Summaries of a few of our top stories appear below.

Our monthly newsletter reaches almost 11,000 people, who have an interest in dementia, from across Europe and beyond.

We are always happy to receive feedback, or suggestions regarding news items to share.



[ https://alzheimereurope.newsweaver.com/Newsletter/1d33r3wn7rd/external?lang=en ]

</description>
<pubDate>31 Mar 2026 12:00:00 CEST</pubDate>
<guid isPermaLink="false">6dfedaeb8d52093b89e3b29fcb00ef9b</guid>
<category>Other Articles</category>
<nw:synopsis>&amp;lt;p style="text-align: justify;"&amp;gt;&amp;lt;span style="font-size: 12px;"&amp;gt;&amp;lt;img align="left" src="https://alzheimereurope.newsweaver.com/v3files/shard1/56305/19/ea8a85fca407401059a769.jpg" style="margin: 5px;" width="133" height="200" hspace="5" vspace="5" alt="Executive Director Jean Georges, June 2024"&amp;gt;Alzheimer Europe's&amp;lt;span style="color: #000000;"&amp;gt;&amp;lt;strong&amp;gt;&amp;nbsp;&amp;lt;/strong&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt;&amp;lt;span style="font-size: 12px;"&amp;gt;&amp;lt;span style="color: #000000;"&amp;gt;&amp;lt;strong&amp;gt;&amp;lt;a href="https://alzheimereurope.newsweaver.com/Newsletter/1d33r3wn7rd/external?lang=en" target="_blank" rel="noreferrer noopener"&amp;gt;&amp;lt;strong&amp;gt;March 2026 newsletter&amp;lt;/strong&amp;gt;&amp;lt;/a&amp;gt;&amp;nbsp;&amp;lt;/strong&amp;gt;&amp;lt;/span&amp;gt;brings you the latest news on developments in the dementia field, across Europe and beyond.&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;
&amp;lt;p style="text-align: justify;"&amp;gt;&amp;lt;span style="font-size: 12px;"&amp;gt;Summaries of a few of our top stories appear below.&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;
&amp;lt;p style="text-align: justify;"&amp;gt;&amp;lt;span style="font-size: 12px;"&amp;gt;Our monthly newsletter reaches almost 11,000 people, who have an interest in dementia, from across Europe and beyond.&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;
&amp;lt;p style="text-align: justify;"&amp;gt;&amp;lt;span style="font-size: 12px;"&amp;gt;We are always happy to receive feedback, or suggestions regarding news items to share.&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;
&amp;lt;p style="text-align: justify;"&amp;gt;&amp;nbsp;&amp;lt;/p&amp;gt;
&amp;lt;p class="centered-only" style="text-align: center;"&amp;gt;&amp;lt;a href="https://alzheimereurope.newsweaver.com/Newsletter/1d33r3wn7rd/external?lang=en" target="_blank" rel="noreferrer noopener"&amp;gt;&amp;lt;img align="middle" src="https://alzheimereurope.newsweaver.com/v3files/shard1/56305/33/9a2b2c753c2ca4ee114ecc.jpg" style="margin: 0px;" width="200" height="48" hspace="0" vspace="0" alt=""&amp;gt;&amp;lt;/a&amp;gt;&amp;lt;/p&amp;gt;
</nw:synopsis>
</item>
<item>
<title>13 March: Our guide on sex, gender and sexuality in dementia is now available in German and French</title>
<link>https://alzheimereurope.newsweaver.com/Newsletter/1ou1016i9a1?lang=en&amp;rss=true</link>
<description>Our guide aimed at raising awareness of issues around sex, gender and sexuality in dementia is now available in German language and in French for the Luxembourg context.

</description>
<pubDate>31 Mar 2026 12:00:00 CEST</pubDate>
<guid isPermaLink="false">2141f933138e172bc7f217b099ec34ae</guid>
<category>Other Articles</category>
<nw:synopsis>&amp;lt;p style="text-align: justify;"&amp;gt;&amp;lt;span style="font-size: 12px;"&amp;gt;&amp;lt;img align="left" src="https://alzheimereurope.newsweaver.com/v3files/shard1/56305/79/5ada203940dfb5c71d7b5a.jpg" style="margin: 5px;" width="150" height="150" hspace="5" vspace="5" alt=""&amp;gt;Our guide aimed at raising awareness of issues around sex, gender and sexuality in dementia is now available in German language and in French for the Luxembourg context.&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;
</nw:synopsis>
<nw:webAddress>https://www.alzheimer-europe.org/news/alzheimer-europe-guide-aimed-raising-awareness-issues-around-sex-gender-and-sexuality-dementia</nw:webAddress>
</item>
<item>
<title>20 March: We are delighted to present a special publication about our 2025 Annual Conference in Bologna!</title>
<link>https://alzheimereurope.newsweaver.com/Newsletter/z0hu2gx4hy7?lang=en&amp;rss=true</link>
<description>We are pleased to present a supplement to our latest Dementia in Europe magazine, focusing on the 35th Alzheimer Europe Conference (35AEC), which took place in Bologna (Italy) in October of last year.

</description>
<pubDate>31 Mar 2026 12:00:00 CEST</pubDate>
<guid isPermaLink="false">2896670507971a7d2eb92dd135a7f685</guid>
<category>Other Articles</category>
<nw:synopsis>&amp;lt;p style="text-align: justify;"&amp;gt;&amp;lt;span style="font-size: 12px;"&amp;gt;&amp;lt;img align="left" src="https://alzheimereurope.newsweaver.com/v3files/shard1/56305/a0/5963402b1a203aa13a71fe.png" style="margin: 5px;" width="150" height="150" hspace="5" vspace="5" alt=""&amp;gt;We are pleased to present a supplement to our latest Dementia in Europe magazine, focusing on the 35th Alzheimer Europe Conference (35AEC), which took place in Bologna (Italy) in October of last year.&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;
</nw:synopsis>
<nw:webAddress>https://www.alzheimer-europe.org/news/we-are-delighted-present-special-publication-about-our-2025-annual-conference-bologna?language_content_entity=en</nw:webAddress>
</item>
<item>
<title>23 March: We are hiring! Want to join our Communications team? Apply today!</title>
<link>https://alzheimereurope.newsweaver.com/Newsletter/2ey8h9siika?lang=en&amp;rss=true</link>
<description>Alzheimer Europe Is looking to immediately recruit a Communications Officer (m/f/x) to join its Communications team. Find our more about the position and apply by 19 April!

</description>
<pubDate>31 Mar 2026 12:00:00 CEST</pubDate>
<guid isPermaLink="false">c1f0bba272f044f4935e6eb0bd0c59cc</guid>
<category>Other Articles</category>
<nw:synopsis>&amp;lt;p style="text-align: justify;"&amp;gt;&amp;lt;span style="font-size: 12px;"&amp;gt;&amp;lt;img align="left" src="https://alzheimereurope.newsweaver.com/v3files/shard1/56305/e0/84313bc7894e2976e78bbc.jpg" style="margin:5px;" width="150" height="150" hspace="5" vspace="5" alt=""&amp;gt;Alzheimer Europe Is looking to immediately recruit a Communications Officer (m/f/x) to join its Communications team. Find our more about the position and apply by 19 April!&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;
</nw:synopsis>
<nw:webAddress>https://www.alzheimer-europe.org/news/we-are-hiring-want-join-our-communications-team-apply-today?language_content_entity=en</nw:webAddress>
</item>
<item>
<title>25 March: Anavex announces withdrawal of European marketing authorisation application for blarcamesine</title>
<link>https://alzheimereurope.newsweaver.com/Newsletter/4hu7xhrelcp?lang=en&amp;rss=true</link>
<description>Anavex Life Sciences has announced the withdrawal of its European marketing authorisation application (MAA) for blarcamesine for the treatment of early Alzheimer’s disease.

</description>
<pubDate>31 Mar 2026 12:00:00 CEST</pubDate>
<guid isPermaLink="false">6c8ab435d2bb300f38d4ea168f598be6</guid>
<category>Other Articles</category>
<nw:synopsis>&amp;lt;p style="text-align: justify;"&amp;gt;&amp;lt;span style="font-size: 12px;"&amp;gt;&amp;lt;img align="left" src="https://alzheimereurope.newsweaver.com/v3files/shard1/56305/e4/2345f5f4c24e34bbe9d649.png" style="margin: 5px;" width="150" height="130" hspace="5" vspace="5" alt=""&amp;gt;Anavex Life Sciences has announced the withdrawal of its European marketing authorisation application (MAA) for blarcamesine for the treatment of early Alzheimer&amp;rsquo;s disease.&amp;lt;/span&amp;gt;&amp;lt;/p&amp;gt;
</nw:synopsis>
<nw:webAddress>https://www.alzheimer-europe.org/news/anavex-announces-withdrawal-european-marketing-authorisation-application-blarcamesine?language_content_entity=en</nw:webAddress>
</item>
</channel>
</rss>
